Explore › Condition › Metastatic hepatocellular carcinoma
Condition

Metastatic hepatocellular carcinoma

Also known as: Metastasis from hepatocellular carcinoma of liver Metastasis from hepatocellular carcinoma of liver (disorder) Metastatic hepatocellular carcinoma Metastatic hepatocellular carcinoma (disorder) Metastatic hepatocellular carcinoma (morphologic abnormality) Metastatic liver cell carcinoma hepatocellular carcinoma; NAFLD; diabetes hepatocellular carcinoma; diabetes hepatocellular carcinoma; nonalcoholic fatty liver disease; diabetes
15 findings 1 paper 8 related entities View in graph →

Related entities

interventions
Metformin1 insulin monotherapy1 Lispro insulin in parenteral dosage form1 Glycemic Control1 Presence of1
outcomes
Hepatocellular carcinoma5
populations
Type 2 Diabetes Patients5
studys
PMC91075295

Findings (50)

None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →

Papers (1)